ArticleNature communications2020
A second generation leishmanization vaccine with a markerless attenuated Leishmania major strain using CRISPR gene editing.
Open access · goldAbstract read
In one paragraph
Article in Nature communications, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers.
0numbers the graph read from it
0cells of the map it votes in
61citing papers in PubMed
14.4field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
61 citing papers in PubMed, 115 citations in OpenAlex.
- A comprehensive review of CRISPR-Cas9-mediated genome editing in Leishmania strains: methodologies, applications, challenges and future directions.Molecular biology reports · 2026Review
- Next-Generation Vaccines Against Neglected Diseases: New Promises from Genetically Modified Live-Attenuated Parasites and RNA Vaccines.Microorganisms · 2026Review
- Report of the Seventh Post-Kala-Azar Dermal Leishmaniasis Consortium meeting, Kolkata, India, 28-29 November 2024.Parasites & vectors · 2026Article
- Leishmaniasis vaccine research: current status and new directions.Parasitology · 2026Review
- Leishmaniasis: pathogenesis, host immunity, and the evolving landscape of immunotherapy and immunochemotherapy.Frontiers in microbiology · 2026Review
- Presence or Emergence of Canine Leishmaniasis, Malawi.Emerging infectious diseases · 2026Article
- Genetic Manipulation Tools in Leishmania: From CRISPR/Cas9 to Vaccine Strategies for Disease Control.Acta parasitologica · 2025Review
- An Update on Clinical and Pathogenic Spectra of Leishmaniasis.Expert reviews in molecular medicine · 2025Review
- CRISPR/Cas9-mediated deletion of a kinetoplast-associated gene attenuates virulence in Leishmania major parasites.Medical microbiology and immunology · 2025Article
- Kharon Is Crucial forPathogens (Basel, Switzerland) · 2025Article
- LmCenNPJ vaccines · 2025Article
- Vaccines in Dermatology-Present and Future: A Review.Vaccines · 2025Review
- Applications of CRISPR in Parasitology.Current pharmaceutical biotechnology · 2025Review
- Downregulation of IRF7-mediated type-I interferon response by LmCenNPJ vaccines · 2024Article
- Advances inPathogens (Basel, Switzerland) · 2024Review
- An update on recombinant vaccines against leishmaniasis.The Indian journal of medical research · 2024Review
- Immunization withVaccines · 2024Article
- Recent Advances in CRISPR/Cas9-Mediated Genome Editing in Leishmania Strains.Acta parasitologica · 2024Review
- The Preclinical Validation of 405 nm Light Parasiticidal Efficacy onMicroorganisms · 2024Article
- Evidence for gene essentiality in Leishmania using CRISPR.PloS one · 2024Article
1 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
28 authors at 7 institutions in 3 countries.
Wen-Wei Zhang *Department of Microbiology and Immunology, McGill University, Montreal, QC, H3A 2B4, Canada.ORCID http://orcid.org/0000-0003-1996-876X
Subir Karmakar *Division of Emerging and Transfusion Transmitted Diseases, CBER, FDA, Silver Spring, MD, 20993, USA.
Sreenivas Gannavaram *Division of Emerging and Transfusion Transmitted Diseases, CBER, FDA, Silver Spring, MD, 20993, USA.
Ranadhir Dey *Division of Emerging and Transfusion Transmitted Diseases, CBER, FDA, Silver Spring, MD, 20993, USA.
Patrick LypaczewskiDepartment of Microbiology and Immunology, McGill University, Montreal, QC, H3A 2B4, Canada.ORCID http://orcid.org/0000-0002-5550-712X
Nevien IsmailDivision of Emerging and Transfusion Transmitted Diseases, CBER, FDA, Silver Spring, MD, 20993, USA.
Abid SiddiquiDivision of Emerging and Transfusion Transmitted Diseases, CBER, FDA, Silver Spring, MD, 20993, USA.
Vahan SimonyanDivision of Emerging and Transfusion Transmitted Diseases, CBER, FDA, Silver Spring, MD, 20993, USA.ORCID http://orcid.org/0000-0002-4868-4785
Fabiano OliveiraVector Molecular Biology Section, Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD, 20852, USA.ORCID http://orcid.org/0000-0002-7924-8038
Iliano V Coutinho-AbreuVector Molecular Biology Section, Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD, 20852, USA.ORCID http://orcid.org/0000-0002-1389-1071
Thiago DeSouza-VieiraVector Molecular Biology Section, Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD, 20852, USA.
Claudio MenesesVector Molecular Biology Section, Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD, 20852, USA.
James OristianVector Molecular Biology Section, Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD, 20852, USA.
Tiago D SerafimVector Molecular Biology Section, Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD, 20852, USA.
Abu MusaDepartment of Parasitology, Institute of Tropical Medicine (NEKKEN), The Joint Usage/Research Center on Tropical Disease, Nagasaki University, Nagasaki, Japan and Nagasaki University Graduate School of Biomedical Sciences Doctoral Leadership Program, Nagasaki, Japan.ORCID http://orcid.org/0000-0003-0662-0078
Risa NakamuraDepartment of Parasitology, Institute of Tropical Medicine (NEKKEN), The Joint Usage/Research Center on Tropical Disease, Nagasaki University, Nagasaki, Japan and Nagasaki University Graduate School of Biomedical Sciences Doctoral Leadership Program, Nagasaki, Japan.
Noushin SaljoughianDepartment of Pathology and Microbiology, Ohio State University, Columbus, OH, 43210, USA.
Greta VolpedoDepartment of Pathology and Microbiology, Ohio State University, Columbus, OH, 43210, USA.
Monika SatoskarDivision of Emerging and Transfusion Transmitted Diseases, CBER, FDA, Silver Spring, MD, 20993, USA.
Sanika SatoskarDivision of Emerging and Transfusion Transmitted Diseases, CBER, FDA, Silver Spring, MD, 20993, USA.
Pradeep K DagurNational Institute of Heart, Lung and Blood Institute, NIH, Bethesda, MD, 20852, USA.
J Philip McCoyNational Institute of Heart, Lung and Blood Institute, NIH, Bethesda, MD, 20852, USA.
Shaden KamhawiVector Molecular Biology Section, Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD, 20852, USA.ORCID http://orcid.org/0000-0003-4304-636X
Jesus G ValenzuelaVector Molecular Biology Section, Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD, 20852, USA.ORCID http://orcid.org/0000-0002-5589-9450
Shinjiro HamanoDepartment of Parasitology, Institute of Tropical Medicine (NEKKEN), The Joint Usage/Research Center on Tropical Disease, Nagasaki University, Nagasaki, Japan and Nagasaki University Graduate School of Biomedical Sciences Doctoral Leadership Program, Nagasaki, Japan.
Abhay R SatoskarDepartment of Pathology and Microbiology, Ohio State University, Columbus, OH, 43210, USA. Abhay.Satoskar@osumc.edu.ORCID http://orcid.org/0000-0001-5989-1520
Greg MatlashewskiDepartment of Microbiology and Immunology, McGill University, Montreal, QC, H3A 2B4, Canada. greg.matlashewski@mcgill.ca.ORCID http://orcid.org/0000-0002-8971-5525
Hira L NakhasiDivision of Emerging and Transfusion Transmitted Diseases, CBER, FDA, Silver Spring, MD, 20993, USA. Hira.Nakhasi@fda.hhs.gov.ORCID http://orcid.org/0000-0003-4941-1620
National Institutes of Health · USMcGill University · CANagasaki University · JPThe Ohio State University · USNational Heart Lung and Blood Institute · USNortheast Ohio Medical University · USCenter for Biologics Evaluation and Research · US
Funding
Molecular approaches to understand vector-host and vector-pathogen interactionsZIAAI000932 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI VALENZUELA, JESUS · 2009 to 2025
$23.1MCIHR
Abstract
Leishmaniasis is a neglected tropical disease caused by Leishmania protozoa transmitted by infected sand flies. Vaccination through leishmanization with live Leishmania major has been used successfully but is no longer practiced because it resulted in occasional skin lesions. A second generation leishmanization is described here using a CRISPR genome edited L. major strain (LmCen
Indexed as
AnimalsCD4-Positive T-LymphocytesClustered Regularly Interspaced Short Palindromic RepeatsDexamethasoneFemaleFlow CytometryGene EditingGenetic EngineeringHumansImmunosuppression TherapyLeishmania majorMacrophagesMiceMice, Inbred BALB CMice, Inbred C57BLPsychodidaeDexamethasoneVaccines, Attenuated
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.